About Bioss Antibodies
Founded in 1999, Bioss Antibodies develops antibodies and research reagents for life science applications. Its products support biological discovery in cancer research, immunology, neuroscience, cell signalling, metabolism, stem cell biology and infectious disease research. Based in the Greater Boston biotechnology region, the company provides tools for protein detection, characterisation and pathway analysis. Researchers use Bioss products in Western blotting, immunohistochemistry, immunofluorescence, flow cytometry, ELISA and immunoprecipitation workflows.
The Bioss Antibodies catalogue includes more than 18,000 primary antibodies, recombinant antibodies, conjugated antibodies, secondary antibodies and matched antibody pairs. It also offers recombinant proteins, native proteins, ELISA kits, biochemical assay kits and reagents for assay development and cell biology research. The portfolio includes antibodies against post-translational modifications, including phosphorylation, acetylation and methylation. These tools support studies of cellular signalling pathways and disease mechanisms. Their products enable biomarker analysis, tissue profiling, functional assays and quantitative target detection.
Europa Biosite’s subsidiaries distribute for Bioss Antibodies in Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Norway, Sweden and the United Kingdom.